Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Obesity treatment stories

Nov 16, 2026

Novo Nordisk's Wegovy shows weight-loss benefit in children as young as six

Novo Nordisk released full Phase 3 trial results showing Wegovy lowered BMI and obesity rates in children aged 6 and older, though younger children who took the drug showed reduced growth rates.

Nov 16, 2026·3 sources
00
Nov 14, 2026

Eli Lilly releases new obesity drug clinical trial data at ObesityWeek

Eli Lilly released new clinical trial data for its obesity drugs at the ObesityWeek 2026 medical conference, showing weight loss benefits, though full results have not yet been published.

Nov 14, 2026·2 sources
00
Nov 11, 2026

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development

Pfizer has struck a deal with Blackstone to receive up to $1.5 billion through 2028 to fund development of an experimental monthly obesity treatment, as the company races to compete in the GLP-1 market without a currently approved weight-loss drug.

Nov 11, 2026·3 sources
00
Nov 8, 2026

Semaglutide improves cardiac structure and hemodynamics in heart failure with preserved ejection fraction

Two placebo-controlled trials presented at the 2026 AHA Scientific Sessions found semaglutide significantly improved cardiac structure, function, and pulmonary artery wedge pressure in patients with heart failure with preserved ejection fraction and obesity.

Nov 8, 2026·2 sources
00
Nov 6, 2026

Eli Lilly strikes deal to sell obesity drugs directly on Hims & Hers platform

Eli Lilly announced a partnership allowing Hims & Hers Health to sell its obesity drugs Zepbound and Foundayo directly on the telehealth platform, sending Hims & Hers shares up more than 7%. The deal marks a significant course change for Hims, which had previously sold compounded GLP-1 knockoffs.

Nov 6, 2026·3 sources
00
Nov 4, 2026

AstraZeneca made $10 billion offer for obesity drugmaker Rhythm Pharmaceuticals

AstraZeneca made a $10 billion takeover offer for Rhythm Pharmaceuticals, which specializes in treatments for metabolic conditions and severe obesity, according to sources familiar with the matter.

Nov 4, 2026·2 sources
00
Oct 26, 2026

Eli Lilly wins court ruling allowing weight-loss drug ads against Novo Nordisk

A US court denied Novo Nordisk's request to temporarily block Eli Lilly from using advertisements claiming its obesity drugs are more powerful, a setback for Novo as it battles to regain market share.

Oct 26, 2026·2 sources
00
Oct 20, 2026

Novo Nordisk's CagriSema shows 25% weight loss in women in late-stage analysis

Novo Nordisk reported that its next-generation obesity drug CagriSema achieved 25% average weight loss in women with obesity or overweight in a post-completion analysis of late-stage trial data.

Oct 20, 2026·2 sources
00
Oct 16, 2026

Eli Lilly's weight-loss pill Foundayo wins EU regulatory backing

The European Medicines Agency's committee recommended approval of Eli Lilly's oral weight-loss drug Foundayo for obesity and diabetes, following Novo Nordisk's Wegovy as the second oral obesity drug to win the agency's backing.

Oct 16, 2026·2 sources
00
Oct 13, 2026

Zealand Pharma partners with Generate Biomedicines on AI obesity drug development worth up to $1.2 billion

Danish obesity-drug developer Zealand Pharma partnered with US biotech company Generate Biomedicines to develop protein-based treatments for obesity and metabolic diseases using AI, in a deal valued at up to $1.2 billion.

Oct 13, 2026·2 sources
00
Oct 7, 2026

Zealand Pharma's petrelintide shows 9.2% weight loss in Phase 2 obesity trial

Zealand Pharma announced positive Phase 2 ZUPREME-2 trial results for its amylin analog petrelintide, which achieved up to 9.2% mean body weight reduction at week 28 versus 2.0% with placebo in people with overweight or obesity and type 2 diabetes. The drug also demonstrated HbA1c reduction of up to 0.65% versus an increase of 0.23% with placebo.

Oct 7, 2026·3 sources
00
Sep 30, 2026

Eli Lilly's Foundayo demonstrates cardiovascular safety in ACHIEVE-4 diabetes trial

Eli Lilly's oral GLP-1 drug Foundayo (orforglipron) met its primary cardiovascular safety endpoint in the Phase 3 ACHIEVE-4 trial, showing non-inferiority to insulin glargine in adults with type 2 diabetes and obesity. The study found a 16% lower risk of MACE-4 and 23% lower risk of MACE-3, though cardiovascular benefits remain unproven.

Sep 30, 2026·6 sources
00
Sep 27, 2026

Novo Nordisk shifts marketing of GLP-1 drugs from obesity 'patients' to lifestyle 'customers'

Novo Nordisk is increasingly positioning its GLP-1 medications as lifestyle drugs for 'customers' rather than obesity medicines for 'patients,' marking a significant shift in how the company markets these treatments. The change comes as the company continues developing next-generation weight loss drugs and expands its product pipeline.

Sep 27, 2026·4 sources
00
Sep 22, 2026

Novo Nordisk CEO says weight-loss pills could capture 50% of obesity market by 2030

Novo Nordisk CEO Mike Doustdar told Reuters that oral weight-loss medications could represent up to half of the global obesity drug market by 2030, as the Danish drugmaker positions itself for a shift toward pill-based treatments alongside its injectable GLP-1 drugs.

Sep 22, 2026·3 sources
00
Sep 21, 2026

Novo Nordisk's CagriSema outperforms Eli Lilly's tirzepatide in weight loss trials

Novo Nordisk announced topline results showing CagriSema achieved 12.4% weight loss versus 9.1% for tirzepatide at 60 weeks in adults with type 2 diabetes in the REIMAGINE 5 trial, and induced 21% weight loss at 68 weeks in people with overweight or obesity without diabetes in the REDEFINE trial.

Sep 21, 2026·2 sources
00
Sep 20, 2026

Man who weighed 49 stone loses 32 stone after doctor's warning during heart surgery

A 46-year-old father standing 6ft 8in tall lost 32 stone after doctors warned him during open-heart surgery that his weight was endangering his life. He now believes he has the best chance of staying with his family.

Sep 20, 2026·1 source
00
Aug 12, 2026

Eli Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide

Eli Lilly filed six lawsuits against U.S. companies accused of illegally selling black-market versions of its experimental obesity drug retatrutide, escalating its campaign against unauthorized sellers before the medicine has won regulatory approval.

Aug 12, 2026·3 sources
00
Aug 10, 2026

UK becomes first European country to approve Eli Lilly's once-daily weight loss pill Foundayo

The UK's Medicines and Healthcare products Regulatory Agency has authorized orforglipron (brand name Foundayo), a once-daily oral medication from Eli Lilly for treating obesity and type 2 diabetes, making the UK the first country in Europe to approve the drug.

Aug 10, 2026·6 sources
00
Aug 3, 2026

Eli Lilly Opens Limited Early Access Program for Experimental Obesity Drug Retatrutide

Pharmaceutical company Eli Lilly announced it will allow a limited number of patients with severe obesity to access its unapproved experimental drug retatrutide through a compassionate use program, following a case where it granted the drug to a 79-year-old patient. The program has strict eligibility criteria that most patients cannot meet.

Aug 3, 2026·7 sources
00
Jul 29, 2026

Brazil Approves Five New GLP-1 Diabetes Drugs Following Ozempic Patent Expiration

Brazil's health regulator Anvisa approved five new injectable GLP-1 drugs for diabetes and obesity treatment, following expedited regulatory reviews after Ozempic's patent expired in the country in March 2026.

Jul 29, 2026·1 source
00
Jul 17, 2026

India approves Wegovy for fatty liver disease treatment

India's drug regulator approved Novo Nordisk's obesity drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease, expanding the drug's approved uses beyond weight loss.

Jul 17, 2026·1 source
00
Jul 15, 2026

Novo Nordisk Receives EU Approval for First Oral GLP-1 Weight-Loss Treatment

The European Commission has approved Novo Nordisk's once-daily Wegovy pill for weight management in adults with obesity or who are overweight, marking the first oral GLP-1 weight-loss treatment cleared for use across the European Union.

Jul 15, 2026·2 sources
00
Jul 14, 2026

Study finds frailty risks with GLP-1 drugs in older adults

A large study found potential signs of frailty in older adults taking Eli Lilly's Zepbound may signal relatively high risks for adverse outcomes, raising concerns about GLP-1 obesity drug use in elderly populations.

Jul 14, 2026·1 source
00
Jun 8, 2026

AstraZeneca's experimental obesity pill achieves 10.5% weight loss in phase II trial

AstraZeneca announced results from a phase II trial showing its oral GLP-1 therapy reduced body weight by 10.5%, positioning the company to compete with Eli Lilly in the race to develop convenient pill-based obesity treatments. The drug is advancing to late-stage trials.

Jun 8, 2026·2 sources
00
Jun 3, 2026

GLP-1 Drugs Show Beneficial Effects Across Multiple Cancer Types, New Research Suggests

Research indicates that GLP-1 drugs may have beneficial effects across many types of cancer, expanding the potential therapeutic applications of this drug class beyond diabetes and obesity.

Jun 3, 2026·1 source
00
May 28, 2026

CVS Health Restores Coverage of Eli Lilly's Zepbound and Adds New Obesity Pill to Drug Plans

CVS Health announced it will add Eli Lilly's weight-loss drug Zepbound back to some of its drug lists as an additional preferred option and begin coverage for the drugmaker's newly approved obesity pill, Forza.

May 28, 2026·2 sources
00
May 21, 2026

Eli Lilly's Retatrutide Achieves Up to 30% Weight Loss in Phase 3 TRIUMPH-1 Trial

Eli Lilly announced positive results from its Phase 3 TRIUMPH-1 trial showing retatrutide, an experimental triple-agonist obesity drug, achieved average weight loss of 28.3% at 80 weeks and 30.3% at 104 weeks on the highest dose, matching weight reduction levels typically seen with bariatric surgery.

May 21, 2026·3 sources
00
May 18, 2026

Trump Invested in Eli Lilly Stock as Administration Boosted Obesity Drug Policies

New ethics disclosures reveal President Trump purchased stock in Eli Lilly and an injectable device manufacturer while his health agencies implemented policies benefiting these companies' obesity drug products.

May 18, 2026·1 source
00
Apr 29, 2026

CMS Extends Temporary Medicare Coverage Program for GLP-1 Obesity Drugs

The Centers for Medicare & Medicaid Services announced that its temporary BALANCE model program to cover GLP-1 drugs for obesity in Medicare will not launch as scheduled in January, effectively extending the current coverage approach.

Apr 29, 2026·1 source
00

Bariatric Surgery Shows Greater Long-Term Cardiovascular Benefits Than GLP-1 Weight-Loss Medications

Mayo Clinic study finds metabolic and bariatric surgery provides significantly greater long-term cardiovascular risk reduction compared to GLP-1 medications in people with obesity, despite both treatments improving heart health.

Apr 29, 2026·1 source
00

Boehringer Ingelheim's Obesity Drug Shows 16.6% Weight Loss in Clinical Trial

Boehringer Ingelheim reported that its experimental obesity drug achieved 16.6% weight loss in clinical trials, marking another entrant in the competitive GLP-1 weight loss drug market.

Apr 29, 2026·1 source
00
Apr 16, 2026

FDA Requests Additional Liver Injury Data on Eli Lilly Obesity Pill Foundayo

The FDA has asked Eli Lilly for more data on liver injury linked to its newly approved obesity pill Foundayo.

Apr 16, 2026·1 source
00

Top claims

  • ▪Almost 80 percent of children aged 6 to under 12 given Wegovy in Novo Nordisk's trial reduced their body mass index by at least 10 percent over 68 weeks
  • ▪In the 68-week trial, 40 percent of children aged 6 to under 12 taking Wegovy were no longer classified as having obesity, compared with none in the placebo group
  • ▪As of November 16, 2026, Novo Nordisk has not announced if or when it will file for regulatory approval to treat children under 12 with Wegovy

People involved

Donald Trump

Subtopics

Lifestyle, Wellness and Nutrition17Weight loss medications & GLP-1 drugs17Weight management16GLP-1 medications15Drug Policy, Pricing & Approval13Clinical trials10Drug Approval and Clinical Trials10Eli Lilly10Pharma10GLP-1 drugs9Novo Nordisk8GLP-1 / Weight-Loss Medications7Weight loss drugs6Zepbound6Pharmaceutical Industry5GLP-14Metabolic health4Cardiovascular health.3Drug development3Clinical evaluation2Clinical Trial Design & Evaluation2Drug safety2Foundao2GLP-1 receptor agonists2

Related timelines

Congress

110 stories

Payments

118 stories

Russia-Ukraine war

136 stories

Trump administration

161 stories

Crypto hacks

100 stories